Inflammation and Immunology Breakthrough:
First in class, Oral Approach to Selectively Targeting Pathogenic Macrophages
Blavatnik Fund for Innovation
Blavatnik
Accelerator Award
Golden Ticket Award
Yale Innovation Summit
Top Prize Nucleate Activator
OUR SCIENCE
EpiTET’s novel targets and molecular glue degrader approach selectively eliminates pathogenic macrophages, the key drivers of chronic inflammation and disease micro-environment without suppressing overall immunity.
KEY PUBLICATIONS
Our approach has the potential to revolutionize the way we treat a number of chronic inflammatory conditions including Endometriosis, Metabolic Disorders (MASH), Cancers, and other conditions.
Build a Better Future with Us.
EpiTET Therapeutics, Inc.
101 College St., Suite 210
New Haven, CT 06510